Quick search:
| Result | Content | Outlet | Published | Research |
|---|---|---|---|---|
| Result | Content | Outlet | Published | Research |
| 1 | Roche MS Trial Woes Highlight Current Perils of Reliance on Eastern Europe | BioSpace | 24 days ago | |
| 2 | AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 for the Treatment of Advanced Parkinson's Disease | Investing News Network | 4 hours ago | |
| 3 | Janssen Showcases Recent Data in Relapsing Multiple Sclerosis at the 2021 European Committee for Treatment and Research in Multiple Sclerosis Congress | PR Newswire | 8 months ago | |
| 4 | TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis | BioSpace | 7 months ago | |
| 5 | Updated MS Guidelines Advocate Earlier, More Aggressive Treatment | Medscape | 7 months ago | |
| 6 | AB Science reports its revenues for the year 2021 and provides an update on its activities | GlobeNewswire | 21 days ago | |
| 7 | Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) USA | English | 7 months ago | |
| 8 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VRT, VLTA and ABBV | Investing News Network | 3 hours ago | |
| 9 | Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine | Pfizer | 23 days ago | |
| 10 | Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder | AstraZeneca | 15 days ago | |
| 11 | Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) | Business Wire | 18 days ago | |
| 12 | Fierce Pharma Asia—Hengrui's global plan; Merck, Kelun's $1.4B cancer deal; Dr. Reddy's Russia business | FiercePharma | 3 hours ago | |
| 13 | AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week® | Investing News Network | 4 days ago | |
| 14 | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and IBM and Encourages Investors to Contact the Firm | Investing News Network | 2 days ago | |
| 15 | #ECTRIMS2021 – Quitting Smoking May Help Slow MS Progression | Multiple Sclerosis News Today | 7 months ago | |
| 16 | #ECTRIMS2021 – Cortical Lesions Predict Long-term Cognition... | Multiple Sclerosis News Today | 7 months ago | |
| 17 | ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important June 6 Deadline in Securities Class Action | ABBV | 2 days ago | |
| 18 | Teva faces lawsuit from Israel over unpaid Copaxone royalties | FiercePharma | 9 days ago | |
| 19 | Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis | Novartis | 2 months ago | |
| 20 | ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis leadership | FiercePharma | 7 months ago | |
| 21 | Looking Beyond the Typical Measures of MS Diagnosis | Medscape | 6 months ago | |
| 22 | Novartis CEO: Leqvio, Pluvicto off to good US launch | FiercePharma | 24 days ago | |
| 23 | Why does Roche think 2022 could end up flat despite 11% Q1 jump? | FiercePharma | 25 days ago | |
| 24 | Biogen CEO's 2021 pay remains level despite Aduhelm tribulations | FiercePharma | 21 days ago | |
| 25 | Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021 | Business Wire | 8 months ago | |
| 26 | New genetic clues on multiple sclerosis risk | Science Daily | 4 months ago | |
| 27 | ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action | ABBV | 4 days ago | |
| 28 | Dimethyl Fumarate Versus Teriflunomide for Relapsing MS | Medscape | 7 months ago | |
| 29 | #ECTRIMS2021 | ATA188 Benefits in SPMS, PPMS Hint at Remyelination | 8 months ago | |
| 30 | Ofatumumab Safety Data Reinforced By Multi-Year Study in Patients With Relapsing Multiple Sclerosis | Pharmacy Times | 7 months ago | |
| 31 | Virtual Care May Help Multiple Sclerosis Patients Even After the Pandemic | Medpage Today | 7 months ago | |
| 32 | Targeting EBV-Infected Cells To Treat Multiple Sclerosis | Technology Networks | 3 months ago | |
| 33 | UPenn Neurologist Wins Barancik Prize for Innovation in MS Research | Multiple Sclerosis News Today | 3 months ago | |
| 34 | Which Agent Best for Neuromyelitis Optica? | Medscape | 7 months ago | |
| 35 | Stem Cell Transplant Benefits in Secondary Progressive MS | Medscape | 7 months ago | |
| 36 | Frequent MRI May Spot Active Secondary Progressive MS More Quickly | Medpage Today | 7 months ago | |
| 37 | New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression | Business Wire | 3 months ago | |
| 38 | New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression | Biogen | Biogen | 2 months ago | |
| 39 | Temelimab Proves Safe at Highest Dose for Multiple Sclerosis in Phase 2 Topline Data | Neurology Live | 2 months ago | |
| 40 | Mitsubishi Tanabe scores FDA nod for oral version of its ALS drug Radicava | FiercePharma | 7 days ago | |
| 41 | AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency | GlobeNewswire | 4 months ago | |
| 42 | The lower basal metabolic rate is associated with increased risk of osteosarcopenia in postmenopausal women | BMC Women's Health | 6 days ago | |
| 43 | Year in Review: Multiple Sclerosis | MedPage Today | Medpage Today | 6 months ago | |
| 44 | Clene Nanomedicine Presents Blinded Interim Update from VISIONARY-MS and Positive Results from REPAIR-MS Phase 2 Clinical Trials | GlobeNewswire | 7 months ago | |
| 45 | Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis | Business Wire | 7 months ago | |
| 46 | New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis | Yahoo Finance | 7 months ago | |
| 47 | ECTRIMS-ACTRIMS 2017 | Medscape | 5 years ago | |
| 48 | The experience of participating in an internet-based cognitive behavioral therapy program among patients with cardiovascular disease and depression: a qualitative interview study | BMC Psychiatry | 25 days ago | |
| 49 | New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis | Novartis | 2 months ago | |
| 50 | TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results | GlobeNewswire | 3 months ago | |
| 51 | Positive safety data for long-term use of MS drug Kesimpta | - pharmaphorum | 7 months ago | |
| 52 | Smoking, Drinking Tied to Increased MS Risk, More Severe Symptoms | Medscape | 2 months ago | |
| 53 | Janssen Demonstrates Its Commitment to Advancing Transformative Solutions for Multiple Sclerosis at ACTRIMS Forum 2022 | PR Newswire | 3 months ago | |
| 54 | New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients | Business Wire | 7 months ago | |
| 55 | Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial | The Lancet | 8 days ago | |
| 56 | AB Science OK'd to Start Masitinib Phase 3 Trial in Progressive MS | Multiple Sclerosis News Today | 5 months ago | |
| 57 | Current Strategies in Treating Cytokine Release Syndrome | ITT | Dove Medical Press | 2 days ago | |
| 58 | Rapid Progress in ALS: A Reflection of Advances in Neuromuscular Disorder Care | Neurology Live | 8 days ago | |
| 59 | Rituximab More Effective Than Other MS Treatments? | Medscape | 7 months ago | |
| 60 | Octave Bioscience Building Evidence Base for Multiple Sclerosis Test to Support Clinical Launch | 360Dx | 3 months ago | |
| 61 | CNM-Au8 Raises Brain Energy Metabolism of RRMS Patients in Trial | Multiple Sclerosis News Today | 10 months ago | |
| 62 | MS News That Caught My Eye: COVID-19 Booster, EBV Treatment, Vitamin D | Multiple Sclerosis News Today | 4 months ago | |
| 63 | Low Neutralizing Antibody Incidence, High Antidrug Antibody Rates Observed in MS With Ublituximab Treatment | Neurology Live | 3 months ago | |
| 64 | European Commission approves PONVORYTM (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features | Business Wire | 12 months ago | |
| 65 | CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis | GlobeNewswire | 8 months ago | |
| 66 | Experts clarify subtypes of multiple sclerosis to improve care and clinical trials | EurekAlert | 2 years ago | |
| 67 | Atara Biotherapeutics: Developing personalized, off-the-shelf therapies for multiple sclerosis | BioPharma-Reporter.com | 9 months ago | |
| 68 | Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update | GuruFocus.com | 5 hours ago | |
| 69 | Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Is Safe, Efficacious Over Long-Term | Neurology Live | 2 months ago | |
| 70 | Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022 | European Medicines Agency | European Medicines Agency | | 3 months ago | |
| 71 | The Latest on Multiple Sclerosis and COVID-19 Vaccines | Medscape | 8 months ago | |
| 72 | Roche says hola to Hispanic, Latinx multiple sclerosis communities | FiercePharma | 2 months ago | |
| 73 | BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update | BioSpace | 2 months ago | |
| 74 | Ublituximab as Relapsing MS Therapy Under FDA Review | Multiple Sclerosis News Today | 5 months ago | |
| 75 | New 4-Year Data Show Genentech's Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder | Business Wire | 7 months ago | |
| 76 | Masitinib Slows Disability Progression in PPMS, Non-active SPMS | Multiple Sclerosis News Today | 3 months ago | |
| 77 | European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm | Labiotech.eu | 3 years ago | |
| 78 | Novartis peer-reviewed safety and tolerability data further strengthens Kesimpta's (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosis | Novartis | 3 months ago | |
| 79 | New Consensus Guideline on Clinical MRI Use in MS | Medscape | 7 months ago | |
| 80 | Progressive MS Phase 3 Trial of Masitinib OK'd to Start in Sweden | Multiple Sclerosis News Today | 3 months ago | |
| 81 | MS Therapy Candidate NVG-291 Cleared to Enroll 2nd Volunteer Group | Multiple Sclerosis News Today | 2 months ago | |
| 82 | Nanocrystals Boost Bioenergetics and Restore Neuronal Health | Genetic Engineering & Biotechnology News | 7 months ago | |
| 83 | Azurity bags FDA nod for grape-flavored multiple sclerosis drug | FiercePharma | 3 months ago | |
| 84 | More Results for Ozanimod: DAYBREAK Data, Cognition and Gray Matter, Biomarker for Relapsing MS | AJMC.com Managed Markets Network | 3 years ago | |
| 85 | Qynapse to present new evidence on the value of QyScore® for the diagnosis and monitoring of multiple sclerosis at ACTRIMS Forum 2022 | PR Newswire | 3 months ago | |
| 86 | Alterations of host-gut microbiome interactions in multiple sclerosis | The Lancet | 4 months ago | |
| 87 | New PBS Listings Will Lower Cost of MS Therapy Kesimpta in Australia | Multiple Sclerosis News Today | 8 months ago | |
| 88 | Link Between Lesion Location and Obstructive Sleep Apnea in Multiple Sclerosis | Neurology Advisor | 3 years ago | |
| 89 | Safety Concern With Fingolimod to Ocrelizumab Switch in MS | Medscape | 2 years ago | |
| 90 | Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis | GlobeNewswire | 1 year ago | |
| 91 | MS Therapy Fampyra Not Eligible To Be Added to NHS for England: NICE | Multiple Sclerosis News Today | 5 months ago | |
| 92 | New Data Shed Light on Racial, Ethnic Diversity in MS | Medscape | 1 month ago | |
| 93 | WVU research suggests interrupting immune response improves multiple sclerosis outcomes | Charleston Gazette-Mail | 1 month ago | |
| 94 | Tackling Secondary Progressive Multiple Sclerosis Early on Benefits Patients in a Number of Ways | Managed Healthcare Executive | 1 year ago | |
| 95 | Dr John Corboy on Research About Stopping Disease-Modifying Therapies for Multiple Sclerosis | AJMC.com Managed Markets Network | 2 years ago | |
| 96 | #ECTRIMS2019 | Is Rituximab a Reasonable Option for MS Patients? | 3 years ago | |
| 97 | Longitudinal relationships between disability and gait characteristics in people with MS | Scientific Reports | Nature.com | 2 months ago | |
| 98 | Need to Know: What Is Acthar Gel? | Multiple Sclerosis News Today | 2 years ago | |
| 99 | After a year as Merck KGaA healthcare CEO, Guenter reflects on I-O bispecific flop, spots new multiple sclerosis strategy | FierceBiotech | 3 months ago | |
| 100 | Three EU Tecfidera Generics Recommended As Biogen Battles For Exclusivity | Generics Bulletin | 3 months ago |